The Latest Analyst Ratings For 4D Molecular Therapeutics
The Latest Analyst Ratings For 4D Molecular Therapeutics
4d分析师评级的最新消息
A clear picture of 4D Molecular Therapeutics's perception among financial...4D Molecular Therapeutics (NASDAQ:FDMT) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
4D Molecular Therapeutics（纳斯达克股票代码：FDMT）在上个季度接受了5位分析师的分析，揭示了从看涨到看跌的一系列观点。
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
下表简要介绍了他们最近的收视率，展示了过去30天中不断变化的情绪，并将其与前几个月进行了比较。
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $38.8, with a high estimate of $40.00 and a low estimate of $36.00. This current average represents a 10.6% decrease from the previous average price target of $43.40.
分析师对12个月目标股价的评估提供了更多见解，显示平均目标价为38.8美元，最高估计为40.00美元，低估值为36.00美元。目前的平均价格比之前的平均目标价43.40美元下降了10.6％。
Understanding Analyst Ratings: A Comprehensive Breakdown
了解分析师评级：全面细分
A clear picture of 4D Molecular Therapeutics's perception among financial...
通过对分析师近期行为...
登录免费看全文
登录/注册